Previous 10 |
Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases An estimated 1 in 5,000 adults worldwide ...
NORTHBROOK, Ill., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will pre...
News, Short Squeeze, Breakout and More Instantly...
Clarus Therapeutics Holdings Inc. Company Name:
CRXT Stock Symbol:
OTCMKTS Market:
Clarus Therapeutics Holdings Inc. Website:
Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ), a pharmaceutical company dedicated to providing solutions to un...
NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary ...